Skadden represented Alnylam Pharmaceuticals, Inc. in its $2.8 billion partnership with Roche to develop and commercialize Alnylam’s investigational RNA interference therapeutic zilebesiran for hypertension.
Skadden, Arps, Slate, Meagher & Flom LLP and Affiliates